A carregar...
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in part, for the significant increase in the survival of patients diagnosed with this disease. Bortezomib was the first proteasome inhibitor to be approved for the therapy of multiple myelom...
Na minha lista:
| Publicado no: | Blood Lymphat Cancer |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6467339/ https://ncbi.nlm.nih.gov/pubmed/31360084 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BLCTT.S82444 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|